Corteva, Inc. Plans Quarterly Dividend of $0.18 (NYSE:CTVA)

Corteva, Inc. (NYSE:CTVA) announced a quarterly dividend on Friday, July 24th. Investors of record on Tuesday, September 1st will be paid a dividend of 0.18 per share on Tuesday, September 15th. This represents a c) dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, September 1st.

Corteva has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 5 consecutive years. Corteva has a dividend payout ratio of 20.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Corteva to earn $4.09 per share next year, which means the company should continue to be able to cover its $0.72 annual dividend with an expected future payout ratio of 17.6%.

Corteva Trading Up 0.5%

Shares of CTVA stock traded up $0.45 during trading hours on Friday, reaching $89.23. 2,484,183 shares of the stock traded hands, compared to its average volume of 3,947,348. Corteva has a 1-year low of $60.53 and a 1-year high of $89.39. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $59.68 billion, a PE ratio of 52.49, a PEG ratio of 2.69 and a beta of 0.56. The business has a fifty day moving average price of $81.25 and a 200 day moving average price of $78.84.

Corteva (NYSE:CTVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.32. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The business had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.64 billion. During the same period last year, the company earned $1.13 earnings per share. Corteva’s quarterly revenue was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities research analysts forecast that Corteva will post 3.75 EPS for the current year.

Wall Street Analysts Forecast Growth

CTVA has been the subject of a number of research reports. CICC Research raised their price objective on Corteva from $80.00 to $93.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Barclays increased their price target on Corteva from $84.00 to $91.00 and gave the stock an “overweight” rating in a research report on Thursday, June 11th. Morgan Stanley upped their target price on shares of Corteva from $84.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. Rothschild & Co Redburn lifted their price objective on Corteva from $80.00 to $90.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, Berenberg Bank increased their price target on Corteva from $68.00 to $78.00 and gave the company a “hold” rating in a research note on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Corteva currently has an average rating of “Moderate Buy” and a consensus price target of $90.19.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.